Latest Pulsatile insulin Stories
Hepatic targeted insulin technology designed to make approved insulin therapies safer and more effective Cleveland, OH (PRWEB) March 31, 2015 Diasome
Diasome Pharmaceuticals, Inc. Announces Two New Board Members Cleveland, Ohio (PRWEB) April 09, 2014 Diasome Pharmaceuticals, Inc.
Hepatic Targeted Nanotechnology Focuses On Providing Better Liver Function To Assist In Weight Loss Cleveland, Ohio (PRWEB) March 06, 2014 Diasome Pharmaceuticals,
A Collaboration Focused on the Continued Development of Diabetes and Obesity Breakthroughs Cleveland, OH (PRWEB) March 04, 2014 Diasome Pharmaceuticals,
A fungicide used on farm crops can induce insulin resistance, a new tissue-culture study finds, providing another piece of evidence linking environmental pollutants to diabetes.
A Penn research team, led by Mitchell Lazar, MD, PhD, director of the Institute for Diabetes, Obesity, and Metabolism at the Perelman School of Medicine, University of Pennsylvania, reports in Nature Medicine that mice in which an enzyme called histone deacetylase 3 (HDAC3) was deleted had massively fatty livers, but lower blood sugar, and were thus protected from glucose intolerance and insulin resistance, the hallmark of diabetes.
New research reveals that insulin applied in therapeutic doses selectively stimulates the formation of new elastic fibers in cultures of human aortic smooth muscle cells.
The research team demonstrated that the major downstream path used by insulin to control the genes is also related to the pathways that control the metabolization of nutrients, as reported by
Researchers at UT Southwestern Medical Center have discovered a hormone pathway that potentially could lead to new ways of treating type 1 diabetes independent of insulin, long thought to be the sole regulator of carbohydrates in the liver.
- Growing in low tufty patches.